• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·ABBOTINDIA.NS
Share

Abbott India Limited Stocks

₹ 26065Last Updated 11.06.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

₹ 5.82B

₹ 26065
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Abbott India Limited is a pharmaceutical enterprise that conducts its operations across India. The company provides an extensive portfolio of medicinal products designed for a broad spectrum of therapeutic areas, including women's health, digestive conditions, metabolic disorders, central nervous system ailments, pain management, premature labor concerns, vitamin supplementation, sleep aids, immunizations, and general consumer health items. Established in 1944, the firm was formerly known as Knoll Pharmaceuticals Limited until it officially adopted the name Abbott India Limited in July 2002. Headquartered in Mumbai, India, it operates as a subsidiary of Abbott Capital India Limited.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of ABBOTINDIA.NS is 32766 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.06.2026 01:34

Rally ahead of SpaceX debut: best day since April for S&P 500 and Nasdaq, oil down 5%

12.06.2026 01:01

SpaceX holds record IPO: Elon Musk's space company raises $75 billion

12.06.2026 00:55

Google discusses producing part of its new AI chip at Samsung factories. Is this a threat to TSMC?

12.06.2026 00:10

BofA raised its rating on Intel stock by two notches at once. What is the bank betting on?

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026